Understanding Chronic Headaches
More than 39 million people in the United States and an estimated 1 billion worldwide live with some form of chronic headache disorder, according to the National Institutes of Health. Defined clinically as headaches occurring on 15 or more days per month for at least three months, chronic headaches encompass conditions ranging from chronic migraine and tension-type headache to cluster headache and medication-overuse headache. The disorder ranks as the second-leading cause of disability globally and the leading cause among individuals under 50.
The personal and economic toll is enormous. Repeated attacks disrupt work, family life and social engagement. Up to 40 percent of patients seen at headache specialty clinics carry a chronic headache diagnosis, and women are three to five times more likely than men to be affected. Despite these figures, millions of patients go underdiagnosed or undertreated.
Innovative Therapies for Relief
Calcitonin gene-related peptide (CGRP) is a neuropeptide that plays a central role in migraine pathophysiology. Since 2018, four FDA-approved monoclonal antibodies — erenumab, fremanezumab, galcanezumab and eptinezumab — have been designed specifically to block CGRP or its receptor. In April 2024, the American Headache Society updated its position statement to recognize these therapies as a first-line option for migraine prevention.
“Moving CGRP-targeting therapies to the first line of treatment could have a transformational impact on the prevention of migraine attacks and their associated burdens,” said Dr. Andrew Charles, MD, FAHS, director of the UCLA Goldberg Migraine Program and president of the American Headache Society.
Charles clarified that the updated guidance removes mandatory step-therapy requirements: “We’re not saying that these therapies are the first-line option; we are saying they are a first-line option. There certainly may be individuals for whom the established therapies may be the ones that we choose, but we don’t want to have to choose those first.”
Clinical trial data and real-world experience indicate these antibodies outperform traditional preventive treatments on measures of efficacy, tolerability and adherence. Serious adverse events remain rare, though insurance access can be a barrier.
Acupuncture has accumulated a growing evidence base as a preventive strategy for chronic headache. A landmark Cochrane systematic review found that acupuncture was at least as effective as prophylactic drug treatment for reducing headache frequency, with fewer side effects. A 2024 review published in Frontiers in Neurology confirmed acupuncture’s role among complementary approaches, noting its potential to modulate pain transmission pathways and reduce neuroinflammation.
Researchers note that acupuncture’s mechanisms remain incompletely understood and that study quality is variable. Nevertheless, major headache societies increasingly acknowledge its role in multimodal management plans, particularly for patients seeking to minimize pharmacological load.
Non-invasive neuromodulation has emerged as an important drug-free option for patients who cannot tolerate medications or prefer adjunct therapies. Several FDA-cleared devices are now available. The Cefaly device delivers transcutaneous electrical stimulation to the supraorbital and supratrochlear nerves for migraine prevention and acute treatment. The gammaCore vagus nerve stimulator and the Spring TMS transcranial magnetic stimulator have also received regulatory clearance for various headache indications.
At the forefront of development is the Salvia BioElectronics PRIMUS system, a subcutaneous craniofacial nerve stimulation device targeting both trigeminal and occipital nerve branches, currently in trials as highlighted at the 2025 NeurologyLive year in review. Research in 2025 has placed growing emphasis on neuromodulation as part of personalized, non-pharmacological strategies for chronic headache management.
Integrating Lifestyle Changes
Clinicians emphasize that emerging pharmacological and procedural therapies do not replace the foundational role of lifestyle modification in chronic headache management. Evidence consistently supports the following as headache-frequency reducers when maintained consistently:
• Sleep hygiene — maintaining regular sleep and wake times to avoid hormonal fluctuations and cortisol disruption that can precipitate attacks.
• Hydration and dietary consistency — skipping meals and dehydration remain among the most commonly reported headache triggers. Keeping a headache diary to identify personal dietary triggers, including alcohol, aged cheeses and artificial sweeteners, is recommended.
• Regular aerobic exercise — studies indicate that 30 to 40 minutes of moderate aerobic activity three times per week can reduce migraine frequency, potentially through endorphin release and reductions in central sensitization.
• Stress management — CBT, mindfulness meditation and progressive muscle relaxation have demonstrated measurable reductions in monthly headache days when practiced consistently.
• Limiting analgesic overuse — taking over-the-counter or prescription headache medications on 10 or more days per month can paradoxically worsen headache frequency through medication-overuse headache, a condition that complicates treatment for a substantial proportion of chronic headache patients.
A 2025 American Headache Society position statement reinforced that goal-setting in chronic migraine prevention should move toward patient-centered outcomes, aiming for fewer than four days per month of moderate-to-severe headache and minimal residual disability — goals that combination pharmacological and lifestyle approaches make increasingly achievable.
Consult with Healthcare Professionals
Despite the proliferation of options, experts warn that chronic headache management is not a do-it-yourself endeavor. The condition involves complex neurological mechanisms, significant comorbidities — including depression, anxiety, sleep disorders and cardiovascular disease — and an individualized response to therapy that requires clinical expertise to navigate.
Patients who experience headaches on 15 or more days per month, whose headaches are increasing in frequency or severity, or who are using acute medications more than twice per week should seek evaluation by a board-certified neurologist or, ideally, a headache specialist certified by the United Council for Neurologic Subspecialties.
Access remains a recognized challenge. A significant proportion of headache patients never receive specialist care. Patients who believe they qualify for newer therapies such as CGRP monoclonal antibodies may face insurer step-therapy requirements demanding documented failure of older generic medications first, though the American Headache Society’s updated 2024 guidance is expected to support appeals of such restrictions.
Sources: American Headache Society; NeurologyLive; National Institutes of Health; Frontiers in Neurology; The Lancet; Global Burden of Disease Study 2021; ClinicalTrials.gov.
